Sort
10,766 grants matching “checkpoint inhibitor”
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
$629,482Dong Moon Shin · Emory University · R01 · FY2025 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
$629,354Rebecca Ashare · State University Of New York At Buffalo · U01 · FY2025 · CA
Focal Adhesion Kinase inhibition for dual targeting of osteosarcoma cells and the tumor microenvironment to prevent metastasis
$629,341Daniel Patrick Regan · Colorado State University · R37 · FY2025 · CA
Genetically engineered mouse model to improve therapy of NUT carcinoma
$629,248Christopher A French · Brigham And Women'S Hospital · R01 · FY2024 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$629,224Cesar M Castro · Massachusetts General Hospital · R01 · FY2024 · CA
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
$628,641Paul K Paik · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Radiation and dendritic cells to hepatomas to improve immunotherapy response
$628,467Sean S Park · Mayo Clinic Rochester · R01 · FY2025 · CA
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
$628,445David Braun · Yale University · R37 · FY2024 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$628,386Jin Wang · Baylor College Of Medicine · R01 · FY2025 · CA
IDO1 and Immunotolerance in Glioblastoma
$628,320Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2022 · NS
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$628,148Noah M Hahn · Johns Hopkins University · R01 · FY2022 · CA
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
$627,890Nicholas C Denko · Ohio State University · R01 · FY2023 · CA
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
$627,705Ruijiang Li · Stanford University · R01 · FY2024 · CA
Oncolytic HSV Immunovirotherapy for brain tumors
$627,491Robert L Martuza · Massachusetts General Hospital · R01 · FY2025 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$627,404Harry H Yoon · Mayo Clinic Rochester · R01 · FY2025 · CA
The Genetics of Ocular Melanoma
$627,386Anne Mary Bowcock · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
Targeted degradation of CDK4 and 6 to overcome treatment resistance in breast cancer
$627,371Prasanna G Alluri · Ut Southwestern Medical Center · R01 · FY2025 · CA
Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening
$627,358Joseph C Wu · Stanford University · R01 · FY2021 · HL
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
$627,344Ruijiang Li · Stanford University · R01 · FY2025 · CA
Development of novel human Fab probes for PET imaging of macrophages
$627,132Bernadette Marquez-Nostra · Yale University · R01 · FY2021 · EB
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
$627,098Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2019 · CA
Oncolytic HSV Immunovirotherapy for brain tumors
$627,061Robert L Martuza · Massachusetts General Hospital · R01 · FY2024 · CA
IDO1 and Immunotolerance in Glioblastoma
$627,010Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2021 · NS
Depleting exosomes to improve responses to immune therapy in HNSCC
$627,000Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · DE
Phase I Clinical Trials of Anticancer Agents
$626,936Charles Erlichman · Mayo Clinic Rochester · U01 · FY2007 · CA